Search company, investor...

AkaRx

Founded Year

2005

Stage

Acq - Fin | Alive

Total Raised

$12.5M

About AkaRx

AkaRx develops therapeutic products including avatrombopag, which is an investigational oral thrombopoietin receptor agonist.

Headquarters Location

Mack Centre IV 4th Floor

Paramus, New Jersey, 07652,

United States

201-909-3000

Missing: AkaRx's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: AkaRx's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing AkaRx

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

AkaRx is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Latest AkaRx News

US FDA approves AkaRx's Doptelet to treat patients with chronic liver disease who have low blood platelets

May 23, 2018

The information provided by BioPortfolio.com is not a substitute for professional medical advice, diagnosis or treatment. The BioPortfolio site is sponsored BioPortfolio Limited with offices at Stafford House, 10 Prince of Wales Road, Dorchester, DT1 1PW, England. If you are a legal copyright holder or a designated agent for such and you believe a post on this website falls outside the boundaries of “Fair Use” and legitimately infringes on your or your client's copyright we may be contacted concerning copyright matters here: Contact BioPortfolio . All rights reserved. All other trademarks recognized. Copyright © 1997-2018 BioPortfolio Limited. Site developed by Alacrify Ltd .

AkaRx Frequently Asked Questions (FAQ)

  • When was AkaRx founded?

    AkaRx was founded in 2005.

  • Where is AkaRx's headquarters?

    AkaRx's headquarters is located at Mack Centre IV, Paramus.

  • What is AkaRx's latest funding round?

    AkaRx's latest funding round is Acq - Fin.

  • How much did AkaRx raise?

    AkaRx raised a total of $12.5M.

  • Who are the investors of AkaRx?

    Investors of AkaRx include PBM Capital Group, Eisai, InterWest Partners, Sutter Hill Ventures and Astellas Venture Management.

  • Who are AkaRx's competitors?

    Competitors of AkaRx include Unither Pharmaceuticals, OcuNexus Therapeutics, Aegerion Pharmaceuticals, NextWave Pharmaceuticals, Omthera Pharmaceuticals and 13 more.

Compare AkaRx to Competitors

E
ENTRA Pharmaceuticals

ENTRA Pharmaceuticals is a specialty pharmaceutical company developing therapies and improving existing treatments in areas with high unmet medical needs. In addition to the company's technology platform, ENTRA possesses strong expertise in preclinical and clinical drug development and commercialization.

S
Savior Lifetec

Savior Lifetec is engaged in the development & manufacture of high quality sterile API (Active Pharmaceutical Ingredients) especially carbapenem antibiotics for generic drug markets.

I
IVREA Pharmaceuticals

IVREA Pharmaceuticals is a specialty pharmaceutical company focused on clinical development and commercialization of novel prescription pharmaceuticals for the treatment of dermatologic conditions. IVREA's pharmaceuticals leverage topical delivery technologies.

G
GeneraMedix

GeneraMedix Inc. is a pharmaceutical company that develops, markets and distributes generic injectable products. nnThe company's MissionnnThe company aims to bring to market generic products where the active pharmaceutical ingredient is difficult to source, manufacturing or regulatory hurdles exist and are difficult to overcome, or where product is in short supply. n

U
United Biomedical

United Biomedical operates as a biopharmaceutical company. The Company develops immunotherapeutics and vaccines for chronic and infectious diseases.

G
GRAPP

Grand River Aseptic Pharmaceutical Packaging is a pharmaceutical contract manufacturing organization (CMO) supporting the rapid development of new biomedicines to the clinical stage in the State of Michigan. Grand River APP is the result of an alliance between Van Andel Institute (www.vai.org) and Grand Valley State University, and is operating as a non-profit, state- and federally funded corporation. Grand River APP's first aims to assure that therapeutics are properly distributed into dosage forms for all-important Phase I and Phase II human clinical trials. This process, Fill/Finish and Lyophilization, will be offered broadly to academic, nonprofit, and for-profit organizations in Michigan and across North America for liquid-based drug candidates that require vialing in an FDA-regulated aseptic clean room environment. Typical products envisioned for Grand River APP services include small molecule drugs, peptides, monoclonal antibodies, therapeutic proteins and nano-medicines. As a consequence, however, Grand River APP cannot process cytotoxic/genotoxic or virally-based candidates (e.g. viral vaccines).

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.